As the healthcare landscape continues to shift, the 340B Drug Pricing Program remains a pivotal part of the conversation for policymakers, healthcare providers, and the pharmaceutical industry. With its goal to stretch scarce federal resources as far as possible in serving the underserved, the 340B program has faced both praise and scrutiny. Looking ahead, Ravin Consultants considers several of the trends and predictions that stand to shape the future of the program. Continue Reading Trends and Predictions for the 340B Drug Discount Program
In the ever-evolving landscape of healthcare, the 340B Drug Pricing Program stands out as a crucial element for enabling healthcare providers to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. Enacted in 1992, the 340B program allows eligible healthcare organizations, referred to as ‘covered entities,’ to obtain outpatient drugs at significantly reduced prices. Continue Reading Maximize 340B Savings with the Drug Pricing Program: Strategies for Healthcare Providers
The 340B Drug Pricing Program offers significant savings on prescription drugs for covered entities, which can be leveraged to make a substantial impact on patient care and the expansion of health services. In this article, Ravin Consultants will delve into how healthcare providers can effectively use the financial benefits gained from the 340B program to enhance the quality of care and increase patient services, ultimately contributing to better health outcomes. Continue Reading Leveraging 340B Savings: Impact on Patient Care and Services
The 340B Drug Pricing Program, while providing substantial financial relief to eligible healthcare organizations, also requires strict adherence to compliance and ethical standards. The integrity of the program hinges on participants upholding these standards to ensure that the benefits reach the intended patient populations. This guide will explore the key aspects of 340B compliance and ethics in the 340B program and offer practical advice for participants. Continue Reading 340B Ethics and Program Compliance: A Guide for Participants
340B Audits are a critical component of the 340B Drug Pricing Program compliance framework. For covered entities, preparing for and responding to audits can be a complex but manageable process. This article aims to provide healthcare providers with insights into the 340B audit process and offer practical steps for effective preparation and response. Continue Reading 340B Audit Preparation and Response
In the realm of healthcare, EPT stands for Expedited Partner Therapy. This practice involves providing STI treatment medication to the sexual partner of a diagnosed patient without the healthcare provider directly treating or seeing the partner. As a 340B consulting firm, Ravin Consultants has seen many facilities struggle to provide EPT care to their patients. In this blog, we will explore what EPT is and how it can benefit 340B patients while also addressing some of the legal cons iderations. Continue Reading Understanding EPT Impact on 340B Patients
The 340B Drug Pricing Program, heralded for its potential to stretch federal dollars and improve patient care, is a collaboration between various stakeholders. Among them, drug manufacturers play a significant role. However, the relationship between manufacturers and covered entities isn’t without its challenges, particularly when it comes to manufacturer restrictions. Understanding and navigating these restrictions is essential for the smooth operation of the program. Continue Reading Navigating 340B Restrictions on Manufacturers
In the intricate world of healthcare, every program has its complexities, rules, and regulations. The 340B Drug Pricing Program is no exception. Navigating its waters requires expertise, experience, and an in-depth understanding of both the program’s intricacies and the broader healthcare landscape. This is where the role of a 340B consultant becomes invaluable. Continue Reading The Role of a 340B Consultant
Pharmacies play a pivotal role in the healthcare ecosystem, serving as the bridge between medical professionals and patients. In the context of the 340B Drug Pricing Program, this role becomes even more pronounced through the involvement of contract pharmacies. These entities are instrumental in ensuring that the benefits of the program reach the intended beneficiaries. Continue Reading The Significance of Contract Pharmacies in the 340B Drug Pricing Program
The intricate framework of the 340B Drug Pricing Program necessitates the collaboration of various stakeholders. Among these key players, Third Party Administrators (TPAs) stand out as pivotal in streamlining the program’s operations and ensuring its successful implementation. But what exactly is a 340B TPA, and why are they so crucial to the program’s ecosystem? Continue Reading 340B Third Party Administrators (TPAs): What You Need to Know
The healthcare landscape in the United States is a complex tapestry of programs, policies, and procedures designed to ensure that patients receive the care they need. Central to this mission is the 340B Drug Pricing Program, a critical initiative aimed at helping healthcare providers stretch scarce federal resources to serve more patients and provide comprehensive care. Continue Reading The 340B Drug Pricing Program: What? Who? How? And Why?
Ready to take your
340B Program to the Next Level?
Schedule your FREE consultation with Ravin Consultants today!
Let's work together to maximize your savings and impact.